GoodRx Holdings (GDRX) Accumulated Depreciation & Amortization (2019 - 2025)

GoodRx Holdings has disclosed Accumulated Depreciation & Amortization across 7 years of filings, most recently posting $22.3 million for Q4 2025.

• Accumulated Depreciation & Amortization for Q4 2025 came in at $22.3 million, up 22.27% year-over-year; the trailing twelve-month figure through Dec 2025 was $22.3 million (up 22.27% YoY), and the FY2025 annual result was $22.3 million, up 22.27% from the prior year.
• Accumulated Depreciation & Amortization came in at $22.3 million for Q4 2025 at GoodRx Holdings, up from $18.2 million in the prior quarter.
• In the past five years, Accumulated Depreciation & Amortization ranged from a high of $22.3 million in Q4 2025 to a low of $5.8 million in Q4 2021.
• The 5-year median for Accumulated Depreciation & Amortization is $13.8 million (2023), against an average of $14.0 million.
• Across the five-year window, Accumulated Depreciation & Amortization soared 173.66% in 2021 and advanced 22.27% in 2025, its largest moves.
• GoodRx Holdings' Accumulated Depreciation & Amortization stood at $5.8 million in 2021, then soared by 67.59% to $9.8 million in 2022, then jumped by 41.12% to $13.8 million in 2023, then jumped by 32.24% to $18.2 million in 2024, then increased by 22.27% to $22.3 million in 2025.
• The last three Accumulated Depreciation & Amortization figures came in at $22.3 million (Q4 2025), $18.2 million (Q4 2024), and $13.8 million (Q4 2023), per Business Quant data.